中医药调控动脉粥样硬化CXCL12/CXCR4生物轴的研究进展  

Research Progress on Relationship between CXCL12/CXCR4 Bioaxis and Atherosclerosis and Regulation of Traditional Chinese Medicine:A Review

作　　者：陈正涛 张愿 李季赢 孙礼强 杨燕 梁清芝 帅垠琦 高泓[1,2] 谢春光 CHEN Zhengtao;ZHANG Yuang;LI Jiying;SUN Liqiang;YANG Yan;LIANG Qingzhi;SHUAI Yinqi;GAO Hong;XIE Chunguang(Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan,China;Traditional Chinese Medicine Regulating Metabolic Diseases Key Laboratory of Sichuan Province,Chengdu 610075,Sichuan,China;First Affiliated Hospital of Army Medical University,Chongqing 400038,China;Jiangxi University of Traditional Chinese Medicine,Nanchang 330004,Jiangxi,China)

机构地区：[1]成都中医药大学附属医院,四川成都610075 [2]代谢性疾病中医药调控四川省重点实验室,四川成都610075 [3]陆军军医大学第一附属医院,重庆400038 [4]江西中医药大学,江西南昌330004

出　　处：《中华中医药学刊》2023年第7期127-135,I0029,共10页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金面上项目(81973585);国家自然科学基金青年科学基金项目(82004354);四川省中医药院士后备人选培养项目(CRS2021067);成都中医药大学附属医院重点实验室项目(21ZS01)。

摘　　要：动脉粥样硬化(Atherosclerosis, AS)是一种以动脉管壁增厚变硬、功能减退为特征的慢性炎症性血管疾病,病变后期可继发斑块内出血、破裂及血栓形成,进而引起相应的组织或器官缺血。由AS引起的动脉粥样硬化性心血管疾病(Atherosclerotic Cardiovascular Disease, ASCVD)是世界上发病率和病死率最高的疾病之一。虽然介入治疗和不断涌现的新药对AS具有显著的防治效果,但其不良反应仍不可忽视,中医药因其不良反应小、作用靶点广泛等优势受到越来越多学者的关注。趋化因子12(Chemokine 12,CXCL12)/趋化因子受体4(Chemokine Ceceptor 4,CXCR4)生物轴是一条重要的趋化因子/趋化因子受体轴,能够调控细胞增殖、动员、分化、归巢、趋化等多种生物学行为。近年来大量研究发现其广泛影响着与AS相关的多种细胞,参与AS的发生发展。CXCL12/CXCR4生物轴已逐渐成为AS防治中重要的靶点。近年来中医药调控CXCL12/CXCR4生物轴进而防治AS已被广泛研究,但目前国内外还未见该领域系统的回顾和总结。将综述CXCL12/CXCR4生物轴与AS之间的关系以明确其在AS中的重要作用,同时对中医药调控该生物轴防治AS的文献进行总结,为AS的中医药临床诊治、基础研究以及药物开发提供一定参考意见。Atherosclerosis(AS)is a chronic inflammatory vascular disease characterized by thickening and hardening of arterial wall and functional decline,which can be followed by bleeding,rupture and thrombosis in plaque at the later stage,and then lead to ischemia of corresponding tissues or organs.Atherosclerotic cardiovascular disease(ASCVD),caused by AS,has one of the highest morbidity and mortality rates in the world.Although interventional therapy and emerging new drugs have significant prevention and treatment effects on AS,its side effects and adverse reactions still cannot be ignored.TCM has attracted more and more scholars'attention due to its advantages of small side effects and wide range of targets.The Chemokine 12(CXCL12)/chemokine receptor 4(CXCR4)biological axis is an important chemokine/chemokine receptor axis,which can regulate a variety of biological behaviors such as cell proliferation,mobilization,differentiation,homing and chemotaxis.In recent years,a large number of studies have found that it extensively affects a variety of as-related cells and participates in the occurrence and development of AS.CXCL12/CXCR4 biological axis has gradually become an important target in the prevention and treatment of AS.In recent years,TCM regulation of CXCL12/CXCR4 biological axis to prevent and treat AS has been widely studied,but there is no systematic review and summary in this field at home and abroad.In this paper,the relationship between CXCL12/CXCR4 biological axis and AS was reviewed to clarify its important role in AS and the literatures on TCM regulation of biological axis in the prevention and treatment of AS were summarized,providing some reference for TCM clinical diagnosis and treatment,basic research and drug development of AS.

关 键 词：动脉粥样硬化 CXCL12/CXCR4生物轴 中医药 综述 

分 类 号：R259.435[医药卫生—中西医结合]